Avm Biotechnology, LLC
WA · Founded 2008 · CIK 0001463741 · Biotech · Private
AVM0703, a small molecule pre-conditioning regimen that induces selective lymphodepletion while sparing platelets, stem cells, and red blood cells, and depletes monocytes to reduce cytokine release sy
avmbio.com →- Grants
- $9.9M
- 13 awards
- Sector median: 1
- Raised
- $5.8M
- 6 Form D · Feb 2020
- 79 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 27
- 7 granted · 20 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2008201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $175,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $1,500,000 | |
| Private capital raised | Form D · SEC | $40,000 | |
| Private capital raised | Form D · SEC | $1,395,213 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted lympho-ablation as an alternative to HSCT to cure T1D | $211,047 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted lympho-ablation as an alternative to HSCT to cure T1D | $211,047 | |
| Private capital raised | Form D · SEC | $2,570,215 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel non-toxic preconditioning regimen for cancer cell therapy | $224,770 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel non-toxic preconditioning regimen for cancer cell therapy | $224,770 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Lymphoablation as an alternative to HSCT to cure T1D | $667,733 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Lymphoablation as an alternative to HSCT to cure T1D | $1,631,314 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients | $999,999 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients | $1,999,998 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · AVM0703 combined with Non-Hodgkin's Lymphoma standard of care to enhance complete response rates without additional toxicities | $399,193 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · AVM0703 combined with Non-Hodgkin's Lymphoma standard of care to enhance complete response rates without additional toxicities | $399,193 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeted Lymphoablation as an alternative to HSCT to cure T1D | $963,581 | |
| Federal grant | Department of Health and Human Services · Phase II · Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients | $999,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy | $992,425 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2339 | DEEPSEQAI LLC | — | — |
| 2340 | Tallac Therapeutics, Inc. | — | $21M |
| 2341 | AION Healthspan, Inc. | — | $2.9M |
| 2342 | Avm Biotechnology, LLC | — | $5.8M |
| 2343 | INFIXION BIOSCIENCE, INC. | — | — |
| 2344 | BioLeap, Inc. | — | $5.0M |
| 2345 | GENOPLAN INC. | — | $4.2M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Theresa DeisherDirector · Executive Officer
- THERESA DEISHERDirector · Executive Officer
- ADAM FOUNTAINPromoter
Patents
- Stable Glucocorticoid Formulationapplication
- Stable Glucocorticoid Formulationgranted
- Methods of Treatment Using ICAM-Modulating Agentsgranted
- Lymphocyte Population and Methods for Producing Sameapplication
- Immunoablative Therapiesgranted
- Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virusapplication
- Lymphocyte Population and Methods for Producing Sameapplication
- Immunoablative Therapiesgranted
- Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapyapplication
- Replacement Of Cytotoxic Preconditioning Before Cellular Immunotherapygranted
- Compositions And Methods To Inhibit Stem Cell And Progenitor Cell Binding To Lymphoid Tissue And For Regenerating Germinal Centers In Lymphatic Tissuesgranted
- Personalized Production Of Biologics And Method For Reprogramming Somatic Cellsgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.